{
  "pathway_name": "esophageal-cancer-clinical-pathways-v1-2025-508h",
  "original_file": "esophageal-cancer-clinical-pathways-v1-2025-508h_extracted.json",
  "processed_at": "2025-03-29T00:55:27.367425",
  "complete_summary": {
    "response": "# COMPREHENSIVE CLINICAL PATHWAY: ESOPHAGEAL CANCER MANAGEMENT\n\n## INTRODUCTION\n\nThis clinical pathway provides evidence-based guidance for the diagnosis, staging, treatment, and surveillance of esophageal cancer, addressing both adenocarcinoma and squamous cell carcinoma across various disease stages. The pathway emphasizes multidisciplinary management throughout the disease continuum and encourages clinical trial participation at all decision points. For assistance with clinical trials, email: CancerClinicalTrialsNavigation@va.gov.\n\n## I. MOLECULAR TESTING PROTOCOLS\n\n### Stage IVB Adenocarcinoma\nConcurrent testing required:\n- **MSI/MMR status:** PCR or IHC methodology (consider both methods for distal tumors or Lynch syndrome suspicion)\n- **HER2 testing:** IHC with reflex to FISH if 2+\n- **PD-L1 by CPS** (Combined Positive Score)\n- **CLDN18 by IHC:** Positivity defined as \u226575% of tumor cells demonstrating moderate-to-strong membranous staining\n\n### Stage IVB Squamous Cell Carcinoma\n- **PD-L1 by CPS** (Combined Positive Score)\n\n### Follow-up for MMR-Deficient/MSI-H Tumors\n**Germline NGS Testing** indicated if:\n- MSH2 or MSH6 loss detected by IHC, OR\n- MLH1 or PMS2 loss by IHC AND MLH1 unmethylated, OR\n- MSI-H without IHC testing AND MLH1 unmethylated\n\n## II. EARLY-STAGE DISEASE MANAGEMENT\n\n### Stage 1A (T1aN0M0) - Both Histologies\n- **Initial approach:** EMR (Endoscopic Mucosal Resection) or ESD (Endoscopic Submucosal Dissection)\n- **If R0 resection achieved:** Proceed to surveillance\n- **If R0 not achieved:** Multidisciplinary discussion (surgery, radiation oncology, medical oncology)\n\n### Stage I (T1bN0M0) - Both Histologies\n1. **Multidisciplinary discussion** to confirm staging\n2. **If surgical candidate:**\n   - Surgical resection\n   - **If R0, lymph node positive:** Refer to Medical Oncology\n   - **If R0, lymph node negative:** Surveillance\n3. **If not surgical candidate:**\n   - **With high-risk features:** Refer to Medical Oncology AND Radiation Oncology\n   - **Without high-risk features:** Refer to Radiation Oncology only\n\n**High-risk features:**\n- Lymphovascular invasion\n- Poorly differentiated tumors\n- Tumor size \u22652cm\n- SM1, SM2 involvement\n- Positive margin on EMR\n\n## III. LOCALLY ADVANCED DISEASE MANAGEMENT\n\n### Adenocarcinoma (Stage T1N1[IIA] to T1-3 N3[IVA])\n1. **Multidisciplinary discussion** to determine surgical candidacy\n2. **If surgical candidate:**\n   - DPYD testing required\n   - **For FLOT4 candidates** (ECOG 0-1):\n     - Preoperative FLOT4\n     - PET/CT assessment\n     - **If resectable:** Surgery \u2192 Postoperative chemotherapy\n     - **If unresectable/new metastases:** Follow metastatic pathway\n   - **For non-FLOT4 candidates:**\n     - Preoperative mFOLFOX6\n     - Same assessment pathway as FLOT4\n3. **If not surgical candidate:**\n   - Carboplatin and paclitaxel weekly with radiation\n   - PET/CT assessment\n   - **If resectable:** Surgery \u2192 Surveillance\n   - **If unresectable/metastatic:** Follow metastatic pathway\n\n### Non-Cervical Squamous Cell Carcinoma (Stages IB-IVA)\n1. **Multidisciplinary discussion** to determine surgical candidacy\n2. **If surgical candidate:**\n   - Carboplatin and paclitaxel with radiation\n   - PET/CT assessment\n   - **If no new metastases:** Surgery\n     - **If complete response:** Surveillance\n     - **If incomplete response:** Evaluate for adjuvant nivolumab (1 year)\n   - **If new metastases:** Follow Stage IV Squamous First Line pathway\n3. **If not surgical candidate:**\n   - Carboplatin and paclitaxel with radiation\n   - Surveillance\n\n### Cervical Squamous/Unresectable Localized Disease\n1. **Multidisciplinary discussion** (include Pulmonary for mid-esophageal tumors)\n2. **Nutritional status assessment**\n3. **Treatment:** Carboplatin and paclitaxel weekly with radiation\n4. **Response assessment:**\n   - **If progression/new metastases:** Follow Squamous Cell First Line pathway\n   - **If no progression:**\n     - **If chemotherapy candidate:** Adjuvant carboplatin/paclitaxel (2 cycles)\n     - **If not chemotherapy candidate:** Surveillance\n\n## IV. METASTATIC ADENOCARCINOMA MANAGEMENT\n\n### Stage IVB MSI-High Adenocarcinoma\n1. **Initial assessment:**\n   - Chemotherapy candidacy\n   - Nutritional status\n   - Palliative care referral\n2. **If chemotherapy candidate:**\n   - DPYD testing required\n   - **If immune checkpoint inhibitor candidate:**\n     - Nivolumab + CAPOX/mFOLFOX6 (patient preference)\n   - **If not immune checkpoint inhibitor candidate:**\n     - CAPOX or mFOLFOX6 alone (patient preference)\n3. **If not chemotherapy candidate:**\n   - **If immune checkpoint inhibitor candidate:** Pembrolizumab\n   - **If not immune checkpoint inhibitor candidate:** Hospice\n\n### Stage IVB HER2-Positive Adenocarcinoma (First Line)\n1. **Initial assessment:**\n   - Confirm HER2-positive status\n   - Chemotherapy candidacy\n   - Nutritional status\n   - Palliative care consideration\n2. **If chemotherapy candidate:**\n   - DPYD testing\n   - **If trastuzumab candidate:**\n     - **PD-L1 CPS \u22651%:** Choose between trastuzumab+pembrolizumab+CAPOX/mFOLFOX6 OR trastuzumab+CAPOX/mFOLFOX6\n     - **PD-L1 CPS <1%:** Choose between trastuzumab+mFOLFOX6 OR trastuzumab+CAPOX\n   - **If not trastuzumab candidate:**\n     - **PD-L1 CPS \u22651%:** Nivolumab+mFOLFOX/CAPOX\n     - **PD-L1 CPS <1%:** mFOLFOX6 or CAPOX alone\n3. **If not chemotherapy candidate:**\n   - Palliative radiation\n   - Consider hospice\n\n### Stage IVB HER2-Positive Adenocarcinoma (Second Line)\n1. **Treatment candidacy assessment:**\n   - **If not candidate:** Hospice\n   - **If candidate:** Evaluate for fam-trastuzumab deruxtecan eligibility\n2. **If fam-trastuzumab deruxtecan eligible:** Administer fam-trastuzumab deruxtecan\n3. **If not eligible:**\n   - **If ramucirumab candidate:** Paclitaxel + ramucirumab\n   - **If not ramucirumab candidate:** Irinotecan or docetaxel\n\n### Stage IVB HER2-Negative Adenocarcinoma (First Line)\n1. **Initial assessment:**\n   - Nutritional status\n   - Palliative care consideration\n   - PD-L1 testing\n   - Chemotherapy candidacy\n2. **If chemotherapy candidate:**\n   - CLDN18 testing by IHC and DPYD testing\n   - **PD-L1 CPS <1:**\n     - **CLDN18.2 positive:** Zolbetuximab + mFOLFOX6/CAPOX\n     - **CLDN18.2 negative:** mFOLFOX6 or CAPOX\n   - **PD-L1 CPS 1-4:**\n     - **CLDN18.2 positive:** Choose between Zolbetuximab+mFOLFOX6/CAPOX OR Nivolumab+mFOLFOX6/CAPOX\n     - **CLDN18.2 negative:** mFOLFOX6/CAPOX OR Nivolumab+mFOLFOX6/CAPOX\n   - **PD-L1 CPS \u22655:** Nivolumab + mFOLFOX6/CAPOX\n3. **If not chemotherapy candidate:** Hospice\n\n### Stage IVB HER2-Negative Adenocarcinoma (Second Line)\n1. **Treatment candidacy assessment:**\n   - **If not candidate:** Hospice\n   - **If candidate:** Evaluate for ramucirumab candidacy\n2. **If ramucirumab candidate:**\n   - Paclitaxel + ramucirumab (preferred) OR\n   - Ramucirumab alone\n3. **If not ramucirumab candidate:** Irinotecan or docetaxel\n\n## V. METASTATIC SQUAMOUS CELL CARCINOMA MANAGEMENT\n\n### Stage IVB Squamous Cell Carcinoma (First Line)\n1. **Initial assessment:**\n   - Immune checkpoint inhibitor candidacy\n   - DPYD testing\n   - Nutritional status\n   - PD-L1 testing\n   - Palliative care consideration\n2. **If immune checkpoint inhibitor candidate:**\n   - **If chemotherapy candidate:** Nivolumab + mFOLFOX6/CAPOX\n   - **If not chemotherapy candidate:** Nivolumab + ipilimumab\n3. **If not immune checkpoint inhibitor candidate:**\n   - **If chemotherapy candidate:** CAPOX or mFOLFOX6\n   - **If not chemotherapy candidate:** Hospice or palliative radiation\n\n### Stage IVB Squamous Cell Carcinoma (Second Line)\n1. **Treatment candidacy assessment:**\n   - **If not candidate:** Hospice\n   - **If candidate:** Assess prior checkpoint inhibitor use\n2. **If prior checkpoint inhibitor received:**\n   - **If neuropathy present:** Irinotecan\n   - **If no neuropathy:** Docetaxel\n3. **If no prior checkpoint inhibitor:**\n   - **If immune checkpoint inhibitor candidate:**\n     - **PD-L1 \u226510%:** Pembrolizumab (every 6 weeks)\n     - **PD-L1 <10%:** Nivolumab (every 4 weeks)\n   - **If not immune checkpoint inhibitor candidate:**\n     - **If neuropathy present:** Irinotecan\n     - **If no neuropathy:** Docetaxel\n\n## VI. ELIGIBILITY CRITERIA & SPECIAL CONSIDERATIONS\n\n### Immune Checkpoint Inhibitor Eligibility\nPatient must NOT have:\n- Active autoimmune disease\n- Primary immune deficiency\n- Concurrent immunosuppression (prednisone equivalent >10mg/day)\n- Prior allogeneic HSCT/solid organ transplant\n\n### Trastuzumab Eligibility\n- HER2-positive disease (IHC 3+ or IHC 2+ with FISH/ISH positive)\n- No significant CV disease (LVEF \u226550%, no MI within 6 months, no unstable angina, no arrhythmia requiring therapy)\n\n### Fam-Trastuzumab Deruxtecan Eligibility\n- Prior trastuzumab treatment in first-line setting\n- LVEF \u226550%\n- No history of ILD/pneumonitis\n- ANC \u22651500/mm\u00b3\n\n### Ramucirumab Eligibility\n- Prior fluoropyrimidine and platinum treatment\n- ECOG PS 0-2\n- ANC \u22651500/mm\u00b3\n- No contraindications: non-healing wounds, recent major surgery, bleeding disorders, recent GI perforation, unstable cardiac conditions, active cocaine use\n\n### DPYD Testing\n- Required before fluoropyrimidine therapy\n- Consult pharmacist for intermediate/poor metabolizers\n- May proceed if waiting 2-3 weeks would endanger patient\n\n## VII. VA PRESUMPTIVE CONDITION INFORMATION\n\n### Atomic Veterans\n- **Exposure:** Veterans exposed to ionizing radiation during military service\n- **Benefit:** Automatic presumption of service connection for esophageal cancer\n\n### Gulf War and Post-9/11 Veterans\n- **Qualifying Service:**\n  - Service on/after September 11, 2001 in Afghanistan, Djibouti, Egypt, Jordan, Lebanon, Syria, Uzbekistan, or Yemen, OR\n  - Service on/after August 2, 1990 in Southwest Asia theater or Somalia\n- **Benefit:** Automatic presumption of service connection for gastrointestinal cancers (includes esophageal)\n\n*Southwest Asia Theater includes: Iraq, Kuwait, Saudi Arabia, neutral zone between Iraq and Saudi Arabia, Bahrain, Qatar, UAE, Oman, Gulf of Aden, Gulf of Oman, Persian Gulf, Arabian Sea, Red Sea, and airspace above these locations*",
    "thinking": "Now I need to create a comprehensive clinical pathway summary for esophageal cancer management based on all the analyzed pages. I'll organize this systematically to cover all aspects of the pathway:\n\n1. Introduction and overview\n2. Initial assessment (including molecular testing protocols)\n3. Early-stage disease management\n4. Locally advanced disease management\n5. Metastatic disease management (adenocarcinoma)\n6. Metastatic disease management (squamous cell carcinoma)\n7. Special considerations\n8. VA presumptive condition information\n\nLet me structure this information in a clinically relevant way:\n\n## 1. Introduction and Overview\n\nThe esophageal cancer clinical pathway provides a structured approach to the diagnosis, staging, and treatment of esophageal cancer based on histology (adenocarcinoma vs. squamous cell carcinoma), staging, and molecular characteristics. The pathway emphasizes a multidisciplinary approach throughout the disease continuum and encourages clinical trial participation at all treatment decision points.\n\n## 2. Initial Assessment and Molecular Testing\n\n### Molecular Testing Protocols\n\n#### For Stage IVB Adenocarcinoma:\n- **Required concurrent testing:**\n  - MSI or MMR status (PCR or IHC methodology)\n  - HER2 IHC (with reflex to FISH if 2+)\n  - PD-L1 by CPS (Combined Positive Score)\n  - Ventana CLDN18 (43-14A) by IHC (positivity defined as \u226575% of tumor cells demonstrating moderate to strong membranous CLDN18 IHC)\n\n#### For Stage IVB Squamous Cell Carcinoma:\n- **Required testing:**\n  - PD-L1 IHC (clone 22C3 with CPS score)\n\n#### Follow-up for Deficient MMR or MSI-H Tumors:\n- **Germline NGS Testing** indicated if:\n  - MSH2 or MSH6 loss detected by IHC, OR\n  - MLH1 or PMS2 loss by IHC AND MLH1 unmethylated, OR\n  - MSH1 without IHC testing AND MLH1 unmethylated\n\n#### Special Considerations:\n- For Lynch Syndrome suspicion: Consider both IHC and PCR for MMR status if:\n  - Distal location of tumor\n  - Personal/family history suspicious for Lynch syndrome\n- Germline testing should include at minimum: EPCAM (deletion), MLH1, MSH2, MSH6, and PMS2\n\n## 3. Early-Stage Disease Management\n\n### Stage 1A T1aN0M0 (Adenocarcinoma or Squamous Cell Carcinoma)\n- Initial treatment with EMR (Endoscopic Mucosal Resection) or ESD (Endoscopic Submucosal Dissection)\n- **If Endoscopic resection R0 achieved (negative margins):**\n  - Proceed to surveillance protocol\n- **If Endoscopic resection R0 not achieved:**\n  - Proceed to multidisciplinary discussion (surgery, radiation oncology, medical oncology)\n\n### Stage I T1bN0M0 (Adenocarcinoma or Squamous Cell Carcinoma)\n- Begin with multidisciplinary discussion to confirm staging\n- **If patient is a surgical candidate:**\n  - Proceed to surgical resection\n  - Post-resection assessment for R0 lymph node status:\n    - If R0 lymph node positive: Refer to Medical Oncology\n    - If R0 lymph node negative: Proceed to surveillance program\n- **If patient is not a surgical candidate:**\n  - Assess for high risk features (lymphovascular invasion, poorly differentiated tumors, tumor size \u2265 2cm, SM1/SM2 involvement, positive margin on EMR):\n    - If high risk features present: Refer to Medical Oncology AND Radiation Oncology\n    - If no high risk features present: Refer to Radiation Oncology only\n\n## 4. Locally Advanced Disease Management\n\n### Stage T1N1(IIA) to T1-3 N3 (IVA) Adenocarcinoma\n- Start with multidisciplinary discussion (surgery, radiation oncology, medical oncology)\n- **If patient is a surgical candidate:**\n  - Administer perioperative chemotherapy\n  - DPYD testing required if not already performed\n  - Assess FLOT4 candidacy (criteria: ECOG 0-1)\n    - **If FLOT4 candidate:**\n      - Administer preoperative FLOT4\n      - Assess response by PET/CT\n      - Evaluate for resectability and metastases:\n        - If unresectable/new metastases: Follow Metastatic pathway\n        - If resectable: Surgery \u2192 Postoperative chemotherapy\n    - **If not FLOT4 candidate:**\n      - Administer preoperative mFOLFOX6\n      - Follow same assessment pathway as FLOT4\n- **If patient is not a surgical candidate:**\n  - Administer Carboplatin and paclitaxel weekly with radiation\n  - Assess response by PET/CT:\n    - If unresectable or new metastases: Follow First Line Adenocarcinoma Metastatic pathway\n    - If resectable: Proceed to surgery \u2192 Surveillance\n\n### Non-Cervical Squamous Cell Carcinoma (T2-T3 N0 (IB-IIB), T1-T2 N1 (IIB), T1-2 N2 (IIIA), T3N1 (IIIA), T4aN0-1 (IIIA), T3N2 (IIIB), T4aN2 (IVA))\n- Begin with multidisciplinary discussion (surgery, radiation oncology, medical oncology)\n- **If patient is a surgical candidate:**\n  - Administer carboplatin and paclitaxel with radiation\n  - Assess response by PET/CT\n  - Evaluate for unresectable disease or new metastases:\n    - If new metastases present: Follow Stage IV Squamous First Line pathway\n    - If no new metastases: Proceed to surgery\n  - Post-surgery evaluation:\n    - If complete response: Surveillance\n    - If incomplete response: Evaluate candidacy for immune checkpoint inhibitor\n      - If candidate: Shared Decision Making regarding adjuvant nivolumab for 1 year\n      - If not candidate: Surveillance\n- **If patient is not a surgical candidate:**\n  - Administer carboplatin and paclitaxel with radiation\n  - Follow with surveillance\n\n### Cervical Squamous or Unresectable Localized Disease\n- Begin with multidisciplinary discussion (surgery, radiation oncology, medical oncology)\n  - For mid-esophageal tumors, referral to Pulmonary to assess tracheal invasion\n- Assess nutritional status (concurrent)\n- Administer carboplatin and paclitaxel (weekly) with radiation\n- Assess for disease progression or new metastases:\n  - If progression or new metastases: Follow Squamous Cell First Line pathway\n  - If no progression:\n    - If candidate for chemotherapy: Adjuvant carboplatin and paclitaxel (2 cycles, every 3 weeks)\n    - If not candidate for chemotherapy: Surveillance\n\n## 5. Metastatic Disease Management - Adenocarcinoma\n\n### Stage IVB Adenocarcinoma - MSI-High (Any T, Any N, M1)\n- Initial assessment includes:\n  - Determine candidacy for chemotherapy\n  - Assess nutritional status\n  - Refer to Palliative Care\n- **If candidate for chemotherapy:**\n  - DPYD testing required\n  - Evaluate immune checkpoint inhibitor candidacy\n    - **If candidate for immune checkpoint inhibitor:**\n      - Shared decision-making between:\n        - Nivolumab + CAPOX\n        - Nivolumab + mFOLFOX6\n    - **If not candidate for immune checkpoint inhibitor:**\n      - Shared decision-making between:\n        - CAPOX alone\n        - mFOLFOX6 alone\n- **If not candidate for chemotherapy:**\n  - Evaluate immune checkpoint inhibitor candidacy:\n    - If candidate: Pembrolizumab\n    - If not candidate: Hospice care\n\n### Stage IVB Adenocarcinoma - MSS, HER2 Positive (First Line)\n- Initial assessment includes:\n  - Confirm HER2 Positive status (IHC score +3 or IHC score of +2 and FISH/ISH positive)\n  - Assess for cytotoxic chemotherapy candidacy\n  - Evaluate nutritional status\n  - Consider palliative care referral\n- **If candidate for chemotherapy:**\n  - DPYD testing required (if not already performed)\n  - Evaluate trastuzumab candidacy (eligibility: HER2-positive disease with no clinically significant CV disease)\n    - **If trastuzumab candidate:**\n      - Assess PD-L1 by CPS:\n        - If PD-L1 CPS \u22651%: Patient preference between trastuzumab+pembrolizumab+CAPOX/mFOLFOX6 or trastuzumab+CAPOX/mFOLFOX6\n        - If PD-L1 CPS <1%: Patient preference between trastuzumab+mFOLFOX6 or trastuzumab+CAPOX\n    - **If not trastuzumab candidate:**\n      - Assess PD-L1 by CPS:\n        - If PD-L1 CPS \u22651%: Patient preference between nivolumab+mFOLFOX/CAPOX\n        - If PD-L1 CPS <1%: Patient preference between mFOLFOX6 or CAPOX alone\n- **If not candidate for chemotherapy:**\n  - Refer to Radiation Oncology (for palliative radiation when appropriate)\n  - Consider Hospice referral\n\n### Stage IVB Adenocarcinoma - MSS, HER2 Positive (Second Line)\n- Assess if candidate for therapy:\n  - If no: Refer to Hospice\n  - If yes: Evaluate for fam-trastuzumab deruxtecan eligibility\n    - **If eligible for fam-trastuzumab deruxtecan:**\n      - Administer fam-trastuzumab deruxtecan\n    - **If not eligible:**\n      - Assess for ramucirumab candidacy\n        - If candidate: Administer paclitaxel and ramucirumab\n        - If not candidate: Administer irinotecan or docetaxel\n\n### Stage IVB Adenocarcinoma - MSS, HER2 Negative (First Line)\n- Initial assessment includes:\n  - Assess nutritional status\n  - Consider palliative care referral\n  - Order PD-L1 testing by CPS\n  - Evaluate candidacy for cytotoxic chemotherapy\n- **If candidate for cytotoxic chemotherapy:**\n  - Proceed with CLDN 18 by IHC and DPYD testing\n  - PD-L1 Assessment Pathway:\n    - If PD-L1 CPS <1:\n      - If CLDN18.2 positive: Zolbetuximab with mFOLFOX6 or CAPOX\n      - If CLDN18.2 negative: mFOLFOX6 or CAPOX\n    - If PD-L1 CPS 1-4:\n      - If CLDN18.2 positive: Patient preference between Zolbetuximab with mFOLFOX6/CAPOX or Nivolumab with mFOLFOX6/CAPOX\n      - If CLDN18.2 negative: mFOLFOX6 or CAPOX or Nivolumab with mFOLFOX6/CAPOX\n    - If PD-L1 CPS \u22655: Nivolumab and mFOLFOX6 or CAPOX\n- **If not candidate for cytotoxic chemotherapy:**\n  - Refer to Hospice\n\n### Stage IVB Adenocarcinoma - MSS, HER2 Negative (Second Line)\n- Assess if candidate for treatment:\n  - If no: Hospice care\n  - If yes: Evaluate for ramucirumab candidacy\n    - **If candidate for ramucirumab:**\n      - Administer ramucirumab + paclitaxel (preferred) or ramucirumab alone\n    - **If not candidate for ramucirumab:**\n      - Administer irinotecan or docetaxel\n\n## 6. Metastatic Disease Management - Squamous Cell Carcinoma\n\n### Stage IVB Squamous Cell Carcinoma (First Line)\n- Initial assessment includes:\n  - Determine candidacy for immune checkpoint inhibitor therapy\n  - DPYD testing (if not previously performed)\n  - Assess nutritional status\n  - Order PD-L1 testing by CPS\n  - Consider palliative care referral\n- **If candidate for immune checkpoint inhibitor:**\n  - Assess if candidate for cytotoxic chemotherapy:\n    - If yes: Nivolumab + mFOLFOX6 or CAPOX\n    - If no: Nivolumab + ipilimumab\n- **If not candidate for immune checkpoint inhibitor:**\n  - Assess if candidate for cytotoxic chemotherapy:\n    - If yes: CAPOX or mFOLFOX6 based on patient preference\n    - If no: Refer to Hospice or Radiation Oncology\n\n### Stage IVB Squamous Cell Carcinoma (Second Line)\n- Assess if candidate for treatment:\n  - If no: Refer to Hospice\n  - If yes: Assess if patient received prior checkpoint inhibitor\n    - **If received prior checkpoint inhibitor:**\n      - Evaluate for neuropathy that precludes taxane use:\n        - If neuropathy present: Administer irinotecan\n        - If no neuropathy: Administer docetaxel\n    - **If no prior checkpoint inhibitor:**\n      - Assess if candidate for immune checkpoint inhibitor:\n        - If yes:\n          - Evaluate PD-L1 expression by CPS:\n            - If PD-L1 expression \u226510%: Pembrolizumab every 6 weeks\n            - If PD-L1 expression <10%: Nivolumab every 4 weeks\n        - If no:\n          - Evaluate for neuropathy that precludes taxane use:\n            - If neuropathy present: Administer irinotecan\n            - If no neuropathy: Administer docetaxel\n\n## 7. Special Considerations\n\n### Immune Checkpoint Inhibitor Eligibility Criteria\n- Patient without active autoimmune disease\n- No primary immune deficiency\n- No concurrent immunosuppression (including prednisone equivalent >10mg/day)\n- No prior allogeneic HSCT/solid organ transplant\n\n### DPYD Testing Considerations\n- Required before fluoropyrimidine-based therapy\n- If results indicate intermediate or poor metabolizer, consult clinical pharmacist\n- Treatment may proceed without results if waiting 2-3 weeks would endanger patient\n\n### HER2 Testing and Trastuzumab Eligibility\n- HER2 Positive defined as IHC score +3 or IHC score of +2 and FISH/ISH positive\n- Trastuzumab contraindications: LVEF< 50%, MI within prior 6 months, unstable angina, cardiac arrhythmia requiring therapy\n\n### Fam-Trastuzumab Deruxtecan Eligibility\n- Must have received trastuzumab in first-line setting\n- Baseline LVEF \u2265 50% and/or no clinically significant cardiac disease\n- No history of interstitial lung disease (ILD) or pneumonitis\n- Absolute neutrophil count (ANC) \u2265 1500/mm\u00b3\n\n### Ramucirumab Eligibility\n- Must have received fluoropyrimidine and platinum agent in first-line setting\n- ECOG Performance Status 0-2\n- ANC \u2265 1500/mm\u00b3\n- Contraindications: Non-healing wound/fracture, major surgery within prior 4 weeks, bleeding disorder or coagulopathy, recent history of GI perforation, unstable cardiac conditions, active cocaine use\n\n### CLDN18.2 Positivity\n- Defined as \u226575% of tumor cells demonstrating moderate to strong membranous CLDN18 IHC\n\n## 8. VA Presumptive Condition Information\n\n### Eligibility Pathways for Esophageal Cancer Disability Benefits\n\n#### Pathway 1: Atomic Veterans\n- **Qualifying Exposure:** Veterans exposed to ionizing radiation during military service\n- **Presumptive Condition:** Cancer of the esophagus\n- **Benefit:** Automatic presumption that esophageal cancer was caused by military service\n- **Outcome:** Eligibility for disability compensation\n\n#### Pathway 2: Gulf War and Post 9/11 Veterans\n- **Qualifying Service Period/Location:** \n  * Service on or after September 11, 2001 in: Afghanistan, Djibouti, Egypt, Jordan, Lebanon, Syria, Uzbekistan, or Yemen\n  * OR\n  * Service on or after August 2, 1990 in the Southwest Asia theater of operations or Somalia\n- **Presumptive Condition:** Gastrointestinal cancer of any type (includes esophageal cancer)\n- **Outcome:** Eligibility for disability compensation\n\n#### Southwest Asia Theater of Operations Definition\n- Includes: Iraq, Kuwait, Saudi Arabia, neutral zone between Iraq and Saudi Arabia, Bahrain, Qatar, United Arab Emirates, Oman, Gulf of Aden, Gulf of Oman, Persian Gulf, Arabian Sea, Red Sea, and airspace above these locations\n\nNow I'll create a comprehensive summary of the entire clinical pathway based on this organization."
  }
}